Vaccine Info

MTBVAC Tuberculosis Vaccine

Authored by
Last reviewed
March 18, 2022
Fact checked by
Robert Carlson, MD

MTBVAC Tuberculosis Vaccine Description 2022

MTBVAC is a live attenuated vaccine against Mycobacterium tuberculosis in development.

It is currently being developed for two purposes: as a more effective and potentially longer-lasting vaccine than BCG for newborns and for the prevention of TB disease in adults and adolescents.

MTBVAC was designed by the genetic research group of Dr. Carlos Martin Montañés of the Department of Microbiology at the University of Zaragoza and Brigitte Gicquel at the Institut Pasteur in Paris.

MTBVAC will start phase 3 clinical trials in Senegal, South Africa and Madagascar in the second half of 2022.

MTBVAC Tuberculosis Vaccine News

March 16, 2022 - Bharat Biotech announced the partnership with BIOFABRI, a Spanish biopharmaceutical company, to join forces to develop, manufacture and market a new tuberculosis vaccine. The vaccine is being manufactured and developed by BIOFABRI, in close collaboration with the University of Zaragoza, IAVI and the Tuberculosis Vaccine Initiative (TBVI). MTBVAC has been designed and discovered by Carlos Martín's team of the University of Zaragoza.

Clinical Trials

No clinical trials found